Women with HR-positive, HER2-negative, axillary node-negative early-stage breast cancer can skip adjuvant chemotherapy. Also today, maintenance chemotherapy is the first treatment advancement for rhabdomyosarcoma in 30 years for younger patients, a tumor analysis suggests testing all MSI-high patients for Lynch Syndrome, and for metastatic castration-resistant prostate cancer, black men have a stronger response to abiraterone (Zytinga).
Listen to the MDedge Daily News podcast for all the details on today’s top news.
We noticed you have an ad blocker enabled. Please whitelist us so we can continue to provide free content.